Swedish Medical Center

Running trials

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Prilenia· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT07074886· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)

  NCT07120945· Medtronic - MITG· Source

• Recruiting

  Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06896916· Phase 1· AbbVie· Source

• Active, not recruiting

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  NCT06855277· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· Phase 2· Calico Life Sciences LLC· Source

• Active, not recruiting

  Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

  NCT06898957· Phase 1· Amgen· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  NCT06646276· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

• Recruiting

  Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

  NCT06631287· Phase 3· Wes Ely· Source

• Active, not recruiting

  TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

  NCT06137807· P+F Products + Features USA Inc.· Source

• Recruiting

  Global Paradise System US Post Approval Study

  NCT06297291· ReCor Medical, Inc.· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Recruiting

  A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  NCT06234605· Phase 1· HiberCell, Inc.· Source

• Active, not recruiting

  Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

  NCT06294236· Phase 1· Sana Biotechnology· Source

• Recruiting

  Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

  NCT05380349· Early phase 1· Swedish Medical Center· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

  NCT06220201· Phase 1· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Enrolling by invitation

  ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

  NCT05932615· Abbott Medical Devices· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06191744· Phase 3· Genmab· Source

• Recruiting

  A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06153251· Phase 1· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Active, not recruiting

  The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

  NCT05820087· HistoSonics, Inc.· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Sanofi· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

  NCT06141473· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  NCT06095089· Phase 1· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)

  NCT05696444· Medtronic - MITG· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Janssen-Cilag Ltd.· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

  NCT05047172· Phase 3· University of Florida· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

  NCT05283720· Phase 2· Genmab· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Biogen· Source

• Active, not recruiting

  A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

  NCT05090371· Phase 4· Novartis Pharmaceuticals· Source

• Recruiting

  Assessment of CCM in HF With Higher Ejection Fraction

  NCT05064709· Impulse Dynamics· Source

• Active, not recruiting

  Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

  NCT04910022· Phase 1/2· Nerviano Medical Sciences· Source

• Recruiting

  PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

  NCT04889872· Edwards Lifesciences· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04961567· Phase 3· Biogen· Source

Showing 50 of 79.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Prostate cancer3 recruiting
• Aortic stenosis2 recruiting
• Heart failure2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple myeloma2 recruiting
• Ovarian cancer2 recruiting
• ALS (motor neurone disease)1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Long COVID and ME/CFS1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Obesity1 recruiting
• Pancreatic cancer1 recruiting
• Polycystic kidney disease1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

  NCT06486454· HistoSonics, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

  NCT05966662· Shockwave Medical, Inc.· Source

• Completed

  Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

  NCT05172024· NYU Langone Health· Source

• Completed

  A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

  NCT05071664· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  NCT05024045· Phase 1· Eli Lilly and Company· Source

• Completed

  Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

  NCT03911739· T. John Winhusen, PhD· Source

• Completed

  Medication Treatment for Opioid Use Disorder in Expectant Mothers

  NCT03918850· Phase 3· T. John Winhusen, PhD· Source

• Completed

  Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

  NCT03911466· T. John Winhusen, PhD· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

• Completed

  A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

  NCT03740529· Phase 1/2· Loxo Oncology, Inc.· Source

• Completed

  A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

  NCT03833180· Phase 1· VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Lipoic Acid for Progressive Multiple Sclerosis (MS)

  NCT03161028· Phase 2· VA Office of Research and Development· Source

• Terminated

  A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

  NCT03530683· Phase 1· Pfizer· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Terminated

  Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

  NCT03382977· Phase 1/2· VBI Vaccines Inc.· Source

• Completed

  PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

  NCT03168776· Sino Medical Sciences Technology Inc.· Source

• Completed

  A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

  NCT03069352· Phase 3· AbbVie· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

  NCT03104374· Phase 3· AbbVie· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

  NCT03104400· Phase 3· AbbVie· Source

• Completed

  AMPLATZER™ Amulet™ LAA Occluder Trial

  NCT02879448· Abbott Medical Devices· Source

• Completed

  A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

  NCT02675231· Phase 2· Eli Lilly and Company· Source

• Completed

  Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

  NCT02486718· Phase 3· Hoffmann-La Roche· Source

• Completed

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217· Mayo Clinic· Source

• Completed

  A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  NCT02163694· Phase 3· AbbVie· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Psoriatic arthritis46 works · 4 trials
• Psoriasis20 works · 4 trials
• Ankylosing spondylitis9 works · 0 trials